Questions across 3 calls

Siddharth Purohit

InvesQ Investment Advisors Private Limited

Acutaas Chemicals Limited

Acutaas Chemicals Limited CC-Jun25.pdf · 2025-07-30

Sir, as you rightly said in the opening remarks that a lot of your growth during this quarter has come from the non-CDMO pharma intermediate segment. So, when the CDMO thing scales up in a couple of years down the line, is it fair to assume that we will further have a much better margin profile in those set of products? I'm not asking for guidance, but a broad understanding.

Okay. And within the CDMO, what will be the key 3 therapies that, top 3 therapies that we'll be targeting on an incremental basis?

Acutaas Chemicals Limited CC-Mar25.pdf · 2025-05-02

Yes. Sir, if you can give some clarity what would be the overall market size of the anticancer intermediate that we are supplying? And is the market big enough for other players to start supplying to -- like now for the same intermediate that is used Nubeqa for basically?

No. particularly for Nubeqa that -- what is the market size that is? And there is another -- probably another Indian player who is trying to scale up in the same intermediate. So what is the addressable market for that particular intermediate? And is it big enough for multiple players to supply that intermediate. That's what I want to know.

Cartrade Tech Limited

Cartrade Tech Limited CC-Dec24.pdf · 2025-01-29

Hi Sir, Most of my question has been answered. Just two clarifications. Sir, what would be our run rate of ESOP like at consolidated level? But if you can give us…

So, it will not be equally divided between the two entities, right? Aneesha Bhandary No. It's in the respective decks. Each of the entities is displayed separately. So, the standalone reflects the consumer group, which is was what Vinay called out the 2.79 crores.